Stephan Schann
Hoofd Techniek/Wetenschap/O&O bij Domain Therapeutics SA
Profiel
Stephan Schann is currently the Chief Scientific Officer at Domain Therapeutics SA since 2008.
He previously worked as a Team Leader at Evotec (UK) Ltd.
Dr. Schann obtained his graduate and doctorate degrees from the University of Strasbourg.
Actieve functies van Stephan Schann
Bedrijven | Functie | Begin |
---|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Hoofd Techniek/Wetenschap/O&O | 01-01-2008 |
Eerdere bekende functies van Stephan Schann
Bedrijven | Functie | Einde |
---|---|---|
Evotec (UK) Ltd.
Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991. | Corporate Officer/Principal | - |
Opleiding van Stephan Schann
University of Strasbourg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Evotec (UK) Ltd.
Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991. | Commercial Services |